Biochemical Engineering Special Interest Group
biological engineering professionals

Latest news

Oxford BioMedica Wins $105M Gene Therapy Contract From Bioverativ

Oxford BioMedica, a leading gene and cell therapy group, today announces that it has completed a major new collaboration & licence agreement with Bioverativ Inc. for the development and manufacturing of lentiviral vectors to treat haemophilia. The agreement includes a licence to use OXB's LentiVector Enabled technology and access to its industrial-scale manufacturing technology. Under the terms of the agreement, Oxford BioMedica will receive a $5 million upfront payment from Bioverativ Oxford BioMedica is also eligible to receive various milestone payments, potentially worth in excess of $100 million, and undisclosed royalties on net sales of Bioverativ's lentiviral vector haemophilia products.

Latest news RSS feed

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).